What is the significance of a heterozygous FIL (α‑0 thalassemia) deletion identified on non‑invasive prenatal testing?

Heterozygous FIL (α-0 Thalassemia) Deletion on NIPT: Clinical Significance

A heterozygous FIL deletion (α-0 thalassemia) identified on NIPT indicates the pregnant woman is a carrier and requires immediate partner testing to determine fetal risk for severe α-thalassemia (hemoglobin Bart's hydrops fetalis), which is lethal without intervention.

Immediate Clinical Action Required

The detection of a heterozygous α-0 thalassemia deletion (such as the Southeast Asian [SEA] deletion) means:

• The mother carries one normal α-globin gene cluster and one deleted cluster
• The fetus has 25% risk of severe α-thalassemia IF the partner is also a carrier
• Partner testing is mandatory to stratify fetal risk 1

Risk Stratification Based on Partner Status

If Partner is Also α-0 Thalassemia Carrier (Both SEA Deletion):

• 25% risk of homozygous α-0 thalassemia (hemoglobin Bart's hydrops fetalis)
• This condition is uniformly lethal in utero or shortly after birth without intervention
• Confirmatory invasive prenatal diagnosis (amniocentesis or CVS) remains the gold standard 1
• NIPT for severe thalassemia has 97.89% sensitivity and 98.56% specificity when both parents carry SEA deletion 2

If Partner Has Normal α-Globin Genes:

• Fetus will be either normal or heterozygous carrier (like mother)
• No risk of severe disease
• No further testing needed

If Partner Has α+ Thalassemia (Single Gene Deletion):

• Fetus could have hemoglobin H disease (moderately severe)
• Consider invasive testing for definitive diagnosis

NIPT Performance Characteristics

Recent studies demonstrate NIPT can reliably detect severe α-thalassemia in at-risk pregnancies:

• Concordance rate of 98.42% with invasive diagnosis 2
• Positive predictive value of 94.90% 2
• Negative predictive value of 99.42% 2
• Can be performed as early as 8 weeks gestation 3

The technology uses targeted capture sequencing of cell-free fetal DNA with modified Bayesian algorithms 2 or haplotype-based analysis 4, 3 to determine fetal genotype.

Critical Counseling Points

Common pitfall: Patients frequently misunderstand carrier status versus disease risk. Studies show only ~50% of couples adequately comprehend genetic information after counseling 5. Therefore:

• Use clear, simple language avoiding medical jargon
• Emphasize that carrier status alone causes no symptoms
• Explain that risk only exists if both parents are carriers
• Document partner testing status explicitly
• Consider visual aids or video-based education 5

Clinical Algorithm

1. Confirm maternal heterozygous α-0 deletion from NIPT result
2. Test partner immediately with CBC (MCV <80 fL or MCH <27 pg suggests carrier) 1
3. If partner screen positive: Perform hemoglobin pattern and molecular testing
4. If both parents are α-0 carriers:
   • Offer invasive prenatal diagnosis (gold standard) 1
   • Alternative: Enhanced NIPT for thalassemia (97.89% sensitivity) 2
   • Discuss pregnancy management options
5. If partner is not α-0 carrier: Reassure and document; no further testing needed

Geographic Considerations

In Southeast Asian populations, ~24% carry α-thalassemia mutations 4, making universal antenatal screening cost-effective 1. The SEA deletion is the most common α-0 mutation in this region, and 97% of couples will have informative SNPs for NIPT analysis 6.

The key message: This finding requires urgent partner testing to determine if the fetus is at risk for lethal severe α-thalassemia, but the mother's carrier status alone does not indicate fetal disease.